Technetium Tc-99m sestamibi

Generic Name: Technetium Tc-99m sestamibi

Brand Names: Cardiolite

Drug Type: Small Molecule

Chemical Formula: C_₃₆H_₆₆N_₆O_₆Tc

CAS Number: 109581-73-9

Unique Ingredient Identifier: 971Z4W1S09

Background: Technetium Tc-99m sestamibi (commonly sestamibi) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands, hence the name sesta (6) MIBI.. Following intravenous injection of the drug, Technetium Tc-99m sestamibi is taken up by the myocardium, parathyroid, and/or breast tissue. The mechanism by which sestamibi localizes to these tissues has not been established. Single photon emission computed tomography (SPECT) is then performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.

Currently available within a preparation kit for injection, Technetium Tc 99m Sestamibi is indicated for: 1) detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects); and 2) evaluating myocardial function and developing information for use in patient management decisions.

Indication: Technetium Tc 99m Sestamibi is indicated for: 1) detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects); and 2) evaluating myocardial function and developing information for use in patient management decisions.

Associated Conditions: Coronary Artery Disease (CAD)

Associated Therapies: -

Clinical Trials

99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients

Phase 4

Terminated

Conditions: Thyroid Cancer

Interventions: Drug: 99mTc sestamibi

First Posted Date: 2017-02-27

Last Posted Date: 2022-07-26

Lead Sponsor: Medstar Health Research Institute

Target Recruit Count: 4

Registration Number: NCT03065218

Locations: 🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States

Stress and Rest Myocardial Tomoscintigraphies Using Mono- or Double-isotope Protocol With a Semiconductor Camera

Not Applicable

Completed

Conditions: Myocardial Perfusion

Interventions: Procedure: Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)
Drug: 99mTc-Sestamibi
Drug: Thallium-201

First Posted Date: 2016-08-16

Last Posted Date: 2016-08-16

Lead Sponsor: Central Hospital, Nancy, France

Target Recruit Count: 118

Registration Number: NCT02869126

Locations: 🇫🇷
Service de Médecine Nucléaire - CLCC Jean Perrin, Clermont Ferrand, France
🇫🇷
Service de Médecine Nucléaire - Hôpital de Brabois, Vandœuvre les Nancy, France

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients with Triple Negative Breast Cancer

Early Phase 1

Active, not recruiting

Conditions: Estrogen Receptor Negative
Progesterone Receptor Negative
HER2/Neu Negative
Triple-Negative Breast Carcinoma

Interventions: Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Other: Laboratory Biomarker Analysis
Radiation: Scintimammography
Drug: Technetium Tc-99m Sestamibi

First Posted Date: 2016-04-20

Last Posted Date: 2024-10-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 96

Registration Number: NCT02744053

Locations: 🇺🇸
MD Anderson in Katy, Houston, Texas, United States
🇺🇸
MD Anderson League City, Nassau Bay, Texas, United States
🇺🇸
Memorial Hermann Memorial City Medical Center, Houston, Texas, United States

and more 3 locations

Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Device: Molecular Breast Imaging
Device: Conventional Mammography
Drug: Technetium (99mTc) sestamibi

First Posted Date: 2013-08-19

Last Posted Date: 2014-08-19

Lead Sponsor: Mayo Clinic

Target Recruit Count: 1638

Registration Number: NCT01925170

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Device: Molecular Breast Imaging
Device: Conventional Mammography
Drug: Technetium (99mTc) sestamibi

First Posted Date: 2008-02-21

Last Posted Date: 2014-08-01

Lead Sponsor: Mayo Clinic

Target Recruit Count: 969

Registration Number: NCT00620373

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects

Phase 1

Completed

Conditions: Kawasaki Disease

First Posted Date: 2005-09-13

Last Posted Date: 2011-06-02

Lead Sponsor: Lantheus Medical Imaging

Target Recruit Count: 79

Registration Number: NCT00162045

Locations: 🇨🇳
Local Institution, Taichung, Taiwan
🇺🇸
Jackson Memorial Hospital, Miami, Florida, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

and more 4 locations